HSM.TO - Helius Medical Technologies, Inc.

Toronto - Toronto Delayed Price. Currency in CAD
11.49
+0.30 (+2.68%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close11.19
Open11.35
Bid10.19 x 0
Ask11.53 x 0
Day's Range11.24 - 11.74
52 Week Range9.00 - 24.50
Volume30,640
Avg. Volume11,773
Market Cap268.388M
Beta (3Y Monthly)2.16
PE Ratio (TTM)N/A
EPS (TTM)-1.77
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.12
  • GlobeNewswire14 hours ago

    Helius Medical Technologies to Release Third Quarter 2018 Financial Results on November 8, 2018

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that third quarter 2018 financial results will be released after the market closes on Thursday, November 8. A live webcast of the call will also be provided on the Events section of the Company's investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. The webcast will be archived on the Events section of the Company’s investor relations website.

  • GlobeNewswire16 days ago

    Helius Medical Technologies and HealthTech Connex Announce Alliance to Build Canadian Commercial Infrastructure

    HealthTech Connex Inc., a Canadian innovative healthcare company and Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius”), a neurotech company focused on neurological wellness, today announced that the Company has entered into an agreement with HealthTech Connex, Inc. (“HTCI”) to develop and manage neuroplasticity clinics in Canada. “The joint venture agreement to establish a new entity called Heuro Canada is an important step in establishing the commercial infrastructure for both the PoNS™ Treatment and the NeuroCatch™ Platform brain measurement in Canada,” said Kirk Fisher, CEO of HealthTech Connex.

  • GlobeNewswire17 days ago

    Helius Medical Technologies and HealthTech Connex Announce Alliance to Build Canadian Commercial Infrastructure

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company has entered into an agreement with HealthTech Connex, Inc. (“HTC”) to develop and manage neuroplasticity clinics in Canada. "We are excited to announce this strategic alliance with HealthTech Connex and look forward to establishing our commercial infrastructure in Canada," said CEO Philippe Deschamps. “The agreement to establish Heuro Canada is an important step in establishing the commercial infrastructure for both the PoNS™ Treatment and the NeuroCatch™ Platform measurement in Canada,” said Kirk Fisher, CEO of HealthTech Connex.

  • GlobeNewswire22 days ago

    Helius Medical Technologies Submits Medical Device License Application to Health Canada for PoNS™ Device

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its wholly owned subsidiary NeuroHabilitation Corporation, submitted an application for a Class II Medical Device License to Health Canada to market its Portable Neuromodulation Stimulator (PoNS™), an investigational medical device. “The Company is pleased to submit our Class II Medical Device License application to market our PoNS Device as an adjunct to physical therapy for the treatment of chronic balance disorder in patients with mild- to moderate-traumatic brain injury,” said Philippe Deschamps, Helius’ President, CEO and Chairman.

  • GlobeNewswire25 days ago

    Helius Medical Technologies to Participate in Three Upcoming Conferences in October

    Live audio webcasts of the MicroCap Conference and Ladenburg Thalmann 2018 Healthcare Conference presentations at the venues will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. Archives of the webcasts will be available for replay following the conferences.

  • Who Are The Top Investors In Helius Medical Technologies Inc (NASDAQ:HSDT)?
    Simply Wall St.29 days ago

    Who Are The Top Investors In Helius Medical Technologies Inc (NASDAQ:HSDT)?

    Every investor in Helius Medical Technologies Inc (NASDAQ:HSDT) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual toRead More...

  • GlobeNewswirelast month

    Helius Announces First Partnership to Implement Clinical Experience Programs With the Investigational PoNS™ Therapy in the United States

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has partnered with The Ohio State University Wexner Medical Center, a leading U.S. neurorehabilitation center located in Columbus, OH to establish the Company’s first Clinical Experience Program for the Company’s Portable Neuromodulation Stimulator (PoNS™), an investigational medical device.

  • GlobeNewswirelast month

    Helius Medical Technologies to Participate in the 20th Annual Global Investment Conference Sponsored by Rodman & Renshaw and H.C. Wainwright & Co.

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced it will be featured as a presenting company at the 20th Annual Global Investment Conference sponsored by Rodman & Renshaw and H.C. Wainwright & Co. at the St. Regis New York in New York, New York. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first product in development is the Portable Neuromodulation Stimulator (PoNS).  For more information, visit www.heliusmedical.com.

  • GlobeNewswirelast month

    Helius Medical Technologies Submits Request for FDA 510(k) Clearance of the PoNS™ Device

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company has submitted a request to the U.S. Food and Drug Administration (“FDA”) for de novo classification and 510(k) clearance of the Portable Neuromodulation Stimulator (PoNS™) device. “Helius is excited to announce the submission of our request for de novo classification and 501(k) clearance of the PoNS device for the treatment of chronic balance deficit due to mild- to moderate-traumatic brain injury,” said Philippe Deschamps, Helius’ President, CEO and Chairman. The Company’s request for de novo classification and 510(k) clearance is supported by clinical data from two double-blind, randomized, controlled trials demonstrating the PoNS device’s safety and efficacy, with combined enrollment of 163 patients.

  • GlobeNewswire3 months ago

    Helius Medical Technologies, Inc. Announces Results of Matters Submitted for Vote at 2018 Annual Shareholder Meeting

    NEWTOWN, Pa., July 23, 2018-- Helius Medical Technologies, Inc. announced today the results of the matters submitted for voting at the annual meeting of shareholders.. The Annual Meeting was held on June ...

  • ACCESSWIRE3 months ago

    Toronto Exchanges Stock Review BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / July 9, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange shaved off 1.81 points, or 0.24%, to finish at 740.10. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).

  • ACCESSWIRE4 months ago

    Today's Free Reports BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / June 7, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange gained 7.25 points, or 0.94%, to finish at 775.10. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).

  • ACCESSWIRE6 months ago

    Canadian Exchanges Stock Scanner BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / May 04, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange shaved off 0.86 points, or 0.11%, to finish at 771.25. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).

  • ACCESSWIRE7 months ago

    Canadian Exchanges Stock Scanner BELLUS Health, Helius Medical Technologies, Resverlogix and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / April 4, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, ...

  • ACCESSWIRE7 months ago

    Today’s Research Reports on ESSA Pharma Inc., Helius Medical Technologies, Inc., ProMetic Life Sciences Inc. and Resverlogix Corp.

    NEW YORK, NY / ACCESSWIRE / March 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE7 months ago

    Toronto Exchanges Stock Review BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / March 5, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, ...

  • ACCESSWIRE9 months ago

    Canadian Exchanges Stock Scanner, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / January 24, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical ...